Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 23936141)

1.

Regulation of the tumor suppressor PTEN through exosomes: a diagnostic potential for prostate cancer.

Gabriel K, Ingram A, Austin R, Kapoor A, Tang D, Majeed F, Qureshi T, Al-Nedawi K.

PLoS One. 2013 Jul 25;8(7):e70047. doi: 10.1371/journal.pone.0070047. Print 2013.

2.

Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer.

Khan S, Jutzy JM, Valenzuela MM, Turay D, Aspe JR, Ashok A, Mirshahidi S, Mercola D, Lilly MB, Wall NR.

PLoS One. 2012;7(10):e46737. doi: 10.1371/journal.pone.0046737. Epub 2012 Oct 16.

3.

Different gDNA content in the subpopulations of prostate cancer extracellular vesicles: apoptotic bodies, microvesicles, and exosomes.

Lázaro-Ibáñez E, Sanz-Garcia A, Visakorpi T, Escobedo-Lucea C, Siljander P, Ayuso-Sacido A, Yliperttula M.

Prostate. 2014 Oct;74(14):1379-90. doi: 10.1002/pros.22853. Epub 2014 Aug 11.

4.

Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer.

Cuzick J, Yang ZH, Fisher G, Tikishvili E, Stone S, Lanchbury JS, Camacho N, Merson S, Brewer D, Cooper CS, Clark J, Berney DM, Møller H, Scardino P, Sangale Z; Transatlantic Prostate Group.

Br J Cancer. 2013 Jun 25;108(12):2582-9. doi: 10.1038/bjc.2013.248. Epub 2013 May 21.

5.

Functional prostate-specific membrane antigen is enriched in exosomes from prostate cancer cells.

Liu T, Mendes DE, Berkman CE.

Int J Oncol. 2014 Mar;44(3):918-22. doi: 10.3892/ijo.2014.2256. Epub 2014 Jan 10.

6.

Conditionally ablated Pten in prostate basal cells promotes basal-to-luminal differentiation and causes invasive prostate cancer in mice.

Lu TL, Huang YF, You LR, Chao NC, Su FY, Chang JL, Chen CM.

Am J Pathol. 2013 Mar;182(3):975-91. doi: 10.1016/j.ajpath.2012.11.025. Epub 2013 Jan 9.

7.

Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression.

Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella RL, Said JW, Isaacs WB, Sawyers CL.

Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50.

8.

Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer.

Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, Kötschau D, Tennstedt P, Huang J, Gerhäuser C, Mader M, Kurtz S, Sirma H, Saad F, Steuber T, Graefen M, Plass C, Sauter G, Simon R, Minner S, Schlomm T.

Am J Pathol. 2012 Aug;181(2):401-12. doi: 10.1016/j.ajpath.2012.04.026. Epub 2012 Jun 13.

9.
10.

Conditional expression of PTEN alters the androgen responsiveness of prostate cancer cells.

Wu Z, Conaway M, Gioeli D, Weber MJ, Theodorescu D.

Prostate. 2006 Jul 1;66(10):1114-23.

PMID:
16637073
11.

Upregulation of miR-153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer.

Wu Z, He B, He J, Mao X.

Prostate. 2013 May;73(6):596-604. doi: 10.1002/pros.22600. Epub 2012 Oct 11.

PMID:
23060044
12.

Neoplastic reprogramming of patient-derived adipose stem cells by prostate cancer cell-associated exosomes.

Abd Elmageed ZY, Yang Y, Thomas R, Ranjan M, Mondal D, Moroz K, Fang Z, Rezk BM, Moparty K, Sikka SC, Sartor O, Abdel-Mageed AB.

Stem Cells. 2014 Apr;32(4):983-97. doi: 10.1002/stem.1619.

13.

Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene expression.

Whelan JT, Kellogg A, Shewchuk BM, Hewan-Lowe K, Bertrand FE.

J Cell Biochem. 2009 Aug 1;107(5):992-1001. doi: 10.1002/jcb.22199.

PMID:
19479935
14.

Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.

Ma X, Ziel-van der Made AC, Autar B, van der Korput HA, Vermeij M, van Duijn P, Cleutjens KB, de Krijger R, Krimpenfort P, Berns A, van der Kwast TH, Trapman J.

Cancer Res. 2005 Jul 1;65(13):5730-9.

15.

Accumulating progenitor cells in the luminal epithelial cell layer are candidate tumor initiating cells in a Pten knockout mouse prostate cancer model.

Korsten H, Ziel-van der Made A, Ma X, van der Kwast T, Trapman J.

PLoS One. 2009 May 22;4(5):e5662. doi: 10.1371/journal.pone.0005662.

16.

Splice variant transcripts of the anterior gradient 2 gene as a marker of prostate cancer.

Neeb A, Hefele S, Bormann S, Parson W, Adams F, Wolf P, Miernik A, Schoenthaler M, Kroenig M, Wilhelm K, Schultze-Seemann W, Nestel S, Schaefer G, Bu H, Klocker H, Nazarenko I, Cato AC.

Oncotarget. 2014 Sep 30;5(18):8681-9.

17.

Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer.

Kim J, Eltoum IE, Roh M, Wang J, Abdulkadir SA.

PLoS Genet. 2009 Jul;5(7):e1000542. doi: 10.1371/journal.pgen.1000542. Epub 2009 Jul 3.

18.

Can urinary exosomes act as treatment response markers in prostate cancer?

Mitchell PJ, Welton J, Staffurth J, Court J, Mason MD, Tabi Z, Clayton A.

J Transl Med. 2009 Jan 12;7:4. doi: 10.1186/1479-5876-7-4.

19.

The role of PTEN in prostate cancer cell tropism to the bone micro-environment.

Wu Z, McRoberts KS, Theodorescu D.

Carcinogenesis. 2007 Jul;28(7):1393-400. Epub 2007 Mar 7.

20.

PTEN deletion and heme oxygenase-1 overexpression cooperate in prostate cancer progression and are associated with adverse clinical outcome.

Li Y, Su J, DingZhang X, Zhang J, Yoshimoto M, Liu S, Bijian K, Gupta A, Squire JA, Alaoui Jamali MA, Bismar TA.

J Pathol. 2011 May;224(1):90-100. doi: 10.1002/path.2855. Epub 2011 Mar 7.

PMID:
21381033
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk